



Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

## **INFORMATION DISCLOSURE STATEMENT BY APPLICANT**

(use as many sheets as necessary)

Sheef

---

1

of 2

Complete if known ATTACHMENT TO #16

Page 11 of 11 | Page 22 of 22 | Date 22/01/2023 | Time 11:45:00 AM

RECEIVED  
DEC 10 2002

TECH CENTER 1600/2900

<p style="text-align: center;"><b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b></p> <p style="text-align: center;">(use as many sheets as necessary)</p> <p>Sheet <b>1</b> of <b>2</b></p>		<p style="text-align: right;"><i>DEMA</i> Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information which contains a burden. CIVIL COMMERCIAL</p> <p style="text-align: right;"><i>substitute for form 1449A/PTO</i></p>			
		<i>RECEIV</i>			
		<i>DEC 10 2002</i>			
		<i>TECH CENTER 16</i>			
				<b>C mplete If Known ATTACH TO #16</b>	
				<b>Application Number</b>	09/618,380
		<b>Filing Date</b>	July 18, 2000		
		<b>First Named Inventor</b>	TSO, J. YUN		
		<b>Art Unit</b>	1642		
		<b>Examiner Name</b>	L. Helms		
		<b>Attorney Docket Number</b>	011823-004920US		

## U.S. PATENT DOCUMENTS

## FOREIGN PATENT DOCUMENTS

Examiner Signature		Date Considered	3/3/03
-----------------------	---	--------------------	--------

<sup>1</sup> Applicant's unique citation designation number (optional). <sup>2</sup> Kind Codes of U.S. Patent Documents at [www.uspto.gov](http://www.uspto.gov) or MPEP 901.04. <sup>3</sup> Enter

Office that issued the document, by the two-letter code (WIPO Standard ST.3).<sup>4</sup> For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document.<sup>5</sup> Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible.<sup>6</sup> Applicant is to place a check mark here if English language Translation is attached.

Patent Home Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231  
PA 3269134 v1



DEC 04 2002

PTO/SB/08B (10-01)

Approved for use through 10/31/2002. OMB 0651-0031

U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number

Substitute for form 1449B/PTO

## INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(use as many sheets as necessary)

Sheet

2

of

2

Complete if Known

Application Number	09/618,380
Filing Date	July 18, 2000
First Named Inventor	TSO, J. YUN
Art Unit	1642
Examiner Name	L. Helms

Attorney Docket Number 011823-004920US TECH CENTER 1600/2900

RECEIVED

DEC 10 2002

OTHER PRIOR ART -- NON PATENT LITERATURE DOCUMENTS			
Examiner Initials *	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T <sup>2</sup>
LAP	AH	BOHLEN et al., "Cytolysis of Leukemic B-Cells by T-Cells Activated via Two Bispecific Antibodies," <u>Blood</u> , 82(6):1803-1812 (1993).	
	AI	BRISSINK, et al., "Treatment of Mice Bearing BCL1 Lymphoma with Bispecific Antibodies," <u>J. Immunol.</u> , 147(11):4019-4026 (1991).	
	AJ	KOSTELNY et al., "Formation of a Bispecific Antibody by the Use of Leucine Zippers," <u>J. Immunology</u> , 148(5):1547-1553 (1992).	
	AK	LINK et al., "Bispecific monoclonal antibody recognizing a neoplastic B-cell antigen and CD3 induces specific cytolysis of neoplastic B-cells by activated peripheral lymphocytes," <u>Proc. American Assn. for Cancer Research</u> , annual meeting, 33:345, abstract (1992).	
	AL	LINK et al., "Production and Characterization of a Bispecific IgG Capable of Inducing T-Cell-Mediated Lysis of Malignant B Cells," <u>Blood</u> , 3343-3349 (1993).	
	AM	LINK et al., "Anti-CD3-Based Bispecific Antibody Designed for Therapy of Human B-Cell Malignancy Can Induce T-Cell Activation by Antigen-Dependant and Antigen-Independent Mechanisms," <u>Int. J. Cancer</u> , 77:251-256 (1998).	
	AN	LINK et al., "Humanized BsF(ab')-2 anti-CD3-based bispecific monoclonal antibody designed for therapy of B-cell malignancies," <u>J. Invest. Med.</u> , 43(supp. 3):428A, abstract (1995).	
	AO	JOLLIFFE, L., "Humanized Antibodies: Enhancing Therapeutic Utility through Antibody Engineering," <u>Intern. Rev. Med.</u> , 10:241-250 (1993).	
↓	AP	WEINER et al., "The Role of T Cell Activation in Anti-CD3 × Antitumor Bispecific Antibody Therapy," <u>J. Immunology</u> , 152(5):2385-2392 (1994).	
LAP	AQ	WEINER et al., "Bispecific Monoclonal Antibody therapy of B-Cell Malignancy," <u>Leukemia and Lymphoma</u> , 16:199-2-7 (1995).	

Examiner Signature		Date Considered	3/3/03
--------------------	---	-----------------	--------

<sup>1</sup> EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>2</sup> Applicant's unique citation designation number (optional). <sup>2</sup> Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.

PA 3269134 v1